Objective
Transcarotid artery revascularization (TCAR) is an increasingly used alternative to carotid endarterectomy. Although the expected length of stay (LOS) after TCAR is typically 1 day, a subset of patients experience prolonged LOS (pLOS), which has important implications for cost, complication risk, and patient recovery. Previous investigations have identified various demographic and clinical risk factors for pLOS after TCAR. However, the role of a preoperative medication regimen is unclear. Our study aims to evaluate the association between specific medication classes, including antihypertensives and antidiabetic agents, and pLOS after TCAR.
Methods
We performed a retrospective, single-institution cohort analysis for all patients who underwent TCAR between 2019 and 2024. Of the 194 patients identified, 131 (67.5%) were stratified into normal LOS (≤1 day) and 63 (32.5%) into pLOS (≥2 days). Demographics, comorbidities, and detailed medication profiles were collected. Logistic regression analyses, adjusted for key covariates, were used to determine associations among medication class, dosage, and pLOS. Statistical significance was set at P < .05.
Results
The rate of pLOS was 32.5% (63/194). Baseline demographics and comorbidities were similar between normal LOS and pLOS groups, with the exception that a history of cerebrovascular accident, stroke, transient ischemic attack, or amaurosis fugax was significantly associated with increased odds of pLOS (odds ratio: 1.89, P < .05). No individual class of antihypertensive, antidiabetic, or diuretic medication was independently associated with pLOS. However, subgroup analyses demonstrated that patients on a low-dose β-blocker had significantly lower odds of pLOS (adjusted odds ratio: 0.82, P = .02). In addition, use of a cardioselective β-blocker was found to be protective against pLOS (adjusted odds ratio: 0.87, P = .04). Other classes of antihypertensives, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers, showed no significant associations with pLOS.
Conclusions
In this single-center, retrospective analysis, preoperative use of a β-blocker, specifically at a low dose with cardioselective agents, was associated with decreased odds of pLOS after TCAR. These findings suggest that medication management may represent a modifiable factor to optimize perioperative outcomes of TCAR. Further prospective studies are warranted to confirm these associations and inform perioperative risk stratification strategies.
扫码关注我们
求助内容:
应助结果提醒方式:
